Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc. (BDTX) priced its initial public offering on Jan 30, 2020 at $19.00 per share, above its $16.00–$18.00 range, raising $201.1M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $652.1M. J.P. Morgan was lead-left underwriter, joined by Jefferies, TD Cowen and Canaccord Genuity. Davis Polk advised the underwriters.

At its 2020 IPO, Black Diamond Therapeutics, Inc. was a preclinical precision oncology company developing small molecule, tumor-agnostic therapies that target undrugged mutations in genetically defined cancers, drawing on cancer genetics, protein structure and medicinal chemistry.

Status

IPO

Ticker

BDTX

Exchange

Nasdaq Global Select

Priced

Jan 30, 2020

IPO price

$19.00

Price range

$16.00–$18.00

Raised

$201.1M

Market cap at IPO price

$652.1M

First filed

Jan 3, 2020

Underwriters

J.P. Morgan, Jefferies, TD Cowen and Canaccord Genuity

Underwriters' counsel

Davis Polk

Sector

Biotech & pharma

Country / state

MA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.